Katherine A High - Net Worth and Insider Trading

Katherine A High Net Worth

The estimated net worth of Katherine A High is at least $24 Million dollars as of 2023-03-28. Katherine A High is the See Remarks of Spark Therapeutics Inc and owns about 210,000 shares of Spark Therapeutics Inc (ONCE) stock worth over $24 Million. Details can be seen in Katherine A High's Latest Holdings Summary section.

Transaction Summary of Katherine A High

To

Katherine A High Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Katherine A High owns 3 companies in total, including CRISPR Therapeutics AG (CRSP) , Incyte Corp (INCY) , and Spark Therapeutics Inc (ONCE) .

Click here to see the complete history of Katherine A High’s form 4 insider trades.

Insider Ownership Summary of Katherine A High

Ticker Comapny Transaction Date Type of Owner
CRSP CRISPR Therapeutics AG 2019-06-11 director
INCY Incyte Corp 2020-03-26 director
ONCE Spark Therapeutics Inc 2019-12-17 director & See Remarks

Katherine A High Latest Holdings Summary

Katherine A High currently owns a total of 1 stock. Katherine A High owns 210,000 shares of Spark Therapeutics Inc (ONCE) as of November 28, 2017, with a value of $24 Million.

Latest Holdings of Katherine A High

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ONCE Spark Therapeutics Inc 2017-11-28 210,000 113.57 23,849,700

Holding Weightings of Katherine A High


Katherine A High Form 4 Trading Tracker

According to the SEC Form 4 filings, Katherine A High has made a total of 0 transactions in Spark Therapeutics Inc (ONCE) over the past 5 years. The most-recent trade in Spark Therapeutics Inc is the sale of 5,000 shares on November 28, 2017, which brought Katherine A High around $356,600.

Insider Trading History of Katherine A High

Ticker
Company
Date
Buy/Sell
Insider Trading Shares
Shares Change
Price
Cost
Final Share
Current Price
Price Change Since Insider Trade (%)
Filing Date
ONCE
Spark Therapeutics Inc
2017-11-28
Sell
5,000.00
-2.33%
$71.32
$356,600.00
210,000.00
$113.57
59.24%
-
ONCE
Spark Therapeutics Inc
2017-10-31
Sell
5,000.00
-2.33%
$83.30
$416,500.00
210,000.00
$113.57
36.34%
-
ONCE
Spark Therapeutics Inc
2017-09-26
Sell
5,000.00
-2.33%
$86.16
$430,800.00
210,000.00
$113.57
31.81%
-
ONCE
Spark Therapeutics Inc
2017-08-29
Sell
10,000.00
-4.55%
$80.25
$802,500.00
210,000.00
$113.57
41.52%
-
ONCE
Spark Therapeutics Inc
2017-07-25
Sell
10,000.00
-4.55%
$72.53
$725,300.00
210,000.00
$113.57
56.58%
-
ONCE
Spark Therapeutics Inc
2017-06-27
Sell
10,000.00
-4.55%
$60.96
$609,600.00
210,000.00
$113.57
86.30%
-
ONCE
Spark Therapeutics Inc
2017-06-19
Sell
10,000.00
-4.55%
$60.00
$600,000.00
210,000.00
$113.57
89.28%
-
ONCE
Spark Therapeutics Inc
2017-04-28
Sell
15,000.00
-6.67%
$58.06
$870,900.00
210,000.00
$113.57
95.61%
-
ONCE
Spark Therapeutics Inc
2017-04-25
Sell
15,000.00
-6.67%
$55.33
$829,950.00
210,000.00
$113.57
105.26%
-
ONCE
Spark Therapeutics Inc
2016-11-14
Sell
10,000.00
-4.55%
$60.30
$603,000.00
210,000.00
$113.57
88.34%
-
ONCE
Spark Therapeutics Inc
2016-09-15
Sell
10,000.00
-4.35%
$60.37
$603,700.00
220,000.00
$113.57
88.12%
-
ONCE
Spark Therapeutics Inc
2016-08-15
Sell
10,000.00
-4.17%
$62.76
$627,600.00
230,000.00
$113.57
80.96%
-
ONCE
Spark Therapeutics Inc
2016-08-10
Sell
1,890.00
-0.78%
$60.00
$113,400.00
240,000.00
$113.57
89.28%
-
ONCE
Spark Therapeutics Inc
2016-08-03
Sell
17,610.00
-6.77%
$60.02
$1,056,950.00
242,390.00
$113.57
89.22%
-
ONCE
Spark Therapeutics Inc
2016-05-24
Sell
10,000.00
-3.70%
$54.00
$540,000.00
260,000.00
$113.57
110.31%
-
ONCE
Spark Therapeutics Inc
2016-05-23
Sell
10,000.00
-3.57%
$54.42
$544,200.00
270,000.00
$113.57
108.69%
-
ONCE
Spark Therapeutics Inc
2015-12-01
Sell
10,000.00
-3.45%
$55.31
$553,100.00
280,000.00
$113.57
105.33%
-
ONCE
Spark Therapeutics Inc
2015-11-16
Sell
10,000.00
-3.33%
$53.77
$537,700.00
290,000.00
$113.57
111.21%
-
ONCE
Spark Therapeutics Inc
2015-10-14
Sell
40,000.00
-11.76%
$49.01
$1,960,400.00
300,000.00
$113.57
131.73%
-
Total 19
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Katherine A High Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Katherine A High Ownership Network

Ownership Network List of Katherine A High

No Data

Ownership Network Relation of Katherine A High


Katherine A High Owned Company Details

What does CRISPR Therapeutics AG do?

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Who are the key executives at CRISPR Therapeutics AG?

Katherine A High is the director of CRISPR Therapeutics AG. Other key executives at CRISPR Therapeutics AG include Chief Medical Officer Phuong Khanh Morrow , Chief Financial Officer Brendan Smith , and Chief Business Officer Lawrence Otto Klein .

CRISPR Therapeutics AG (CRSP) Insider Trades Summary

Over the past 18 months, Katherine A High made no insider transaction in CRISPR Therapeutics AG (CRSP). Other recent insider transactions involving CRISPR Therapeutics AG (CRSP) include a net sale of 225,000 shares made by Samarth Kulkarni ,

In summary, during the past 3 months, insiders sold 50,000 shares of CRISPR Therapeutics AG (CRSP) in total and bought 0 shares, with a net sale of 50,000 shares. During the past 18 months, 225,000 shares of CRISPR Therapeutics AG (CRSP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 225,000 shares.

CRISPR Therapeutics AG (CRSP)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

CRISPR Therapeutics AG Insider Transactions

20/Page
Total 0
Ticker
Insider
Position
Date
Buy/Sell
Shares
Shares Owned
Trade Price($)
Trade Percentage(%)
Cost($1000)
Price change since trade(%)
Share ownership details
Filing Date
20/Page
Total 0

Katherine A High Mailing Address

Above is the net worth, insider trading, and ownership report for Katherine A High. You might contact Katherine A High via mailing address: 3737 Market Street, Suite 1300, Philadelphia Pa 19104.